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 Abstract. Racemic fluoxetine is a widely used SSRI anti-
depressant compound having also anticonvulsant effect. In
addition, it was shown that it blocked several types of voltage
gated ion channels including neural and cardiac calcium
channels. In the present study the effects of enantiomers of
fluoxetine (R(-)-fluoxetine and S(+)-fluoxetine) were compared
on neuronal and cardiac voltage-gated Ca2+ channels using
the whole cell configuration of patch clamp techniques, and
the anticonvulsant action of these enantiomers was also
evaluated in a mouse epilepsy model. In isolated pyramidal
neurons of the dorsal cochlear nucleus of the rat the effect
of fluoxetine (S(+), R(-) and racemic) was studied on the
Ca2+ channels by measuring peak Ba2+ current during ramp
depolarizations. All forms of fluoxetine reduced the Ba2+
current of the pyramidal cells in a concentration-dependent
manner, with a Kd value of 22.3±3.6 µM for racemic fluoxetine.
This value of Kd was higher by one order of magnitude than
found in cardiac myocytes with fluoxetine enantiomers (2.4±0.1
and 2.8±0.2 µM). Difference between the effects of the two
enantiomers on neuronal Ba2+ current was observed only at
5 µM concentration: R(-)-fluoxetine inhibited 28±3% of the
peak current, while S(+)-fluoxetine reduced the current by
18±2% (n=13, P<0.05). In voltage clamped canine ventricular
cardiomyocytes both enantiomers of fluoxetine caused a
reversible concentration-dependent block of the peak Ca2+
current measured at 0 mV. Significant differences between
the two enantiomers in this blocking effect was observed at
low concentrations only: S(+)-fluoxetine caused a higher
degree of block than R(-)-fluoxetine (56.3±2.2% versus
49.1±2.2% and 95.5±0.9% versus 84.5±3.1% block with 3 and
10 µM S(+) and R(-)-fluoxetine, respectively, P<0.05, n=5).
Studied in current clamp mode, micromolar concentrations
of fluoxetine shortened action potential duration of isolated
ventricular cells, while higher concentrations also suppressed
maximum velocity of depolarization and action potential
amplitude. This shortening effect was significantly greater
in the case of S(+) than R(-)-fluoxetine at 1 and 3 µM
concentrations, whereas no differences in their effects on
depolarization were observed. In pentylenetetrazole-induced
mouse epilepsy model fluoxetine pretreatment significantly
increased the 60 min survival rate, survival duration and seizure
latency. These effects were more pronounced with the R(-)
than the S(+) enantiomer. The results indicate that fluoxetine
exerts much stronger suppressive effect on cardiac than
neuronal calcium channels. At micromolar concentrations
(between 1 and 10 µM) R(-)-fluoxetine is more effective than
the S(+) enantiomer on neuronal, while less effective on
cardiac calcium channels. The stronger anticonvulsant effect
of the R(-) enantiomer may, at least partially, be explained by
these differences. Used as an antidepressant or anticonvulsant
drug, less severe cardiac side-effects are anticipated with the
R(-) enantiomer.
Introduction
Fluoxetine is a widely used antidepressant compound, its
action is primarily attributed to inhibition of the reuptake of
serotonin (SSRI) in the central nervous system. Recent studies
indicated, however, that fluoxetine had several additional
effects, many of them involving inhibition of various types of
ion channels, such as muscular and neuronal nicotinic receptors
(1,2), volume-regulated anion channels (3), delayed rectifier
K+ channels in smooth muscle cells (4), voltage-gated Na+
and K+ channels in neurons (5,6) and epithelial cells (7),
voltage-gated Ca2+ channels in cardiac myocytes (8), nerve
terminals (9) and hippocampal pyramidal cells (10).
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Several reports indicated that some conventional anti-
epileptic drugs were found to inhibit Ca2+ channels (11-14),
and vice versa, dihydopyridine type Ca2+ channel blockers
were claimed to suppress epileptiform activity (15-18). There-
fore, it is not surprising that fluoxetine was found to enhance
the anticonvulsant potency of traditionally used antiepileptic
drugs (19,20), and moreover, the drug exerted franc anti-
convulsant action in animal as well as human studies (21-25).
Beyond the antidepressant and anticonvulsive actions of
fluoxetine discussed above, cardiovascular side-effects, like
dysrhythmias, atrial fibrillation, bradycardia (26-33) and
syncope (34-38) were reported in association with fluoxetine
treatment and overdose in man. These cases appear to be due
to the inhibitory action of fluoxetine on cardiac Ca2+ and Na+
channels (8).
In all of the cited studies and case reports racemic
fluoxetine was applied. However, pharmacological properties
of enantiomers of fluoxetine were recently published (39-41).
The two enantiomers of fluoxetine were found to be nearly
equipotent inhibitors of serotonin reuptake but S(+)-fluoxetine
was more slowly eliminated than the R(-) enantiomer (39,40).
Based on their different pharmacokinetic properties and an
absence of central stimulant effect of S(+)-fluoxetine, the
S(+) enantiomer is currently developped as an antimigraine
drug, while R(-)-fluoxetine was suggested for treatment of
depression (39,41). The goal of the present study was to
compare the effects of fluoxetine enantiomers in suppression
of neuronal and cardiac Ca2+ channels, and to study the two
enantiomers separately in a mouse epilepsy model.
Materials and methods
Ion current measurements in cochlear neurons isolated from
rat brain. The neuron isolation procedure was similar to that
described earlier (42). Briefly, after the decapitation of the 5
to 11-day-old rat (n=15) the brain was removed into ice-cold
artificial cerebrospinal fluid (aCSF), where Na+ was replaced
by equimolar sucrose (‘low sodium’ aCSF). The normal aCSF
contained: 125 mM NaCl; 2.5 mM KCl; 10 mM glucose;
1.25 mM NaH2PO4; 26 mM NaHCO3; 2 mM CaCl2; 1 mM
MgCl2; 3 mM myo-inositol; 0.5 mM ascorbic acid; 2 mM Na-
pyruvate. Osmolarity of the aCSF solution was 335 mOsm/l,
and the pH was set to 7.2 by NaOH. The dorsal cochlear
nuclei were then removed and put into an incubation chamber
containing normal aCSF, supplemented with 0.03 mg/ml
collagenase (type IA, Sigma) plus 0.12 mg/ml pronase (type
XIV, Sigma), for 50 min at 31˚C. The incubating solution
was gassed with carbogen (95% O2/5% CO2). The enzyme
treatment was terminated transferring the tissue to normal
aCSF containing 1 mg/ml trypsin inhibitor (type I-S, Sigma).
Neurons were isolated by gentle trituration with fire-polished
Pasteur pipette in HEPES buffered aCSF, containing: 135 mM
NaCl; 3 mM KCl; 10 mM glucose; 10 mM HEPES; 30 mM
sucrose; 2 mM CaCl2; 1 mM MgCl2. After dissociation, the
cells were allowed to settle for 30 min prior to the experiments.
Recording of ion currents was performed at room
temperature (20-22˚C). The isolated cells were visualized
by using an inverted microscope (Nikon Diaphot 300, Japan)
equipped with phase-contrast optics. Cells with triangular
body were selected for the current study. Patch pipettes were
fabricated from thick-walled borosilicate glass (BioLogic
Science Products, Germany). The pipette resistance was
1.5-2 MΩ when filled with the pipette solution, containing:
145 mM N-methyl-D-glucamine; 40 mM HEPES; 4 mM
MgCl2; 5 mM EGTA; 12 mM phosphocreatinine; 2 mM
MgATP; 0.5 mM Na3GTP (type II-S). The pH of this solution
was adjusted to 7.3 by application of HCl. After the cells
settled down and adhered to the bottom of the experimental
chamber, the bath solution was changed to HEPES buffered
aCSF supplemented with the following channel blockers to
minimize the interfering currents: 1 µM tetrodotoxin; 1 mM
CsCl; 2 mM 4-aminopyridine and 5 mM TEA. In addition,
the Ca2+ content of this solution was replaced by 5 mM Ba2+
in order to increase the amplitude of the ionic current flowing
through the high-voltage activated Ca2+ channels. Thus, the
charge carrier was Ba2+ when measuring currents through Ca2+
channels. When the effect of fluoxetine was investigated,
fluoxetine was dissolved in the Ba2+ based extracellular solution
described above, and this solution was applied with a gravity-
driven perfusion system, similarly to the application of the
control extracellular solution. The currents were recorded in the
whole cell configuration of the patch clamp technique by using
an Axopatch 200A amplifier connected to a TL-1 interface
(Axon Instruments, CA). Data acquisition and analysis was
achieved by the pClamp 6.0 software (Axon Instruments,
CA). Digitization rate was 5 kHz and the current signals were
filtered at 2 kHz with a 4-pole Bessel filter. The capacitive
transients were electronically compensated, while leak
correction was performed by measuring the leak current evoked
by small voltage steps from a holding potential of -75 mV,
and subtracting the extrapolated leak current from the total
current. Series resistance varied between 2.5 and 17 MΩ,
and it was compensated by at least 40%. No correction was
made for the junction potential typically of 2-3 mV.
Electrophysiological measurements in isolated canine
ventricular myocytes. Single canine ventricular myocytes
were obtained from hearts of adult mongrel dogs using the
segment perfusion technique as described earlier (43).
Briefly, the animals (10-20 kg) were anesthetized with i.v.
injection of 10 mg/kg ketamine hydrochloride (Calypsolvet)
plus 1 mg/kg xylazine hydrochloride (Rometar). After opening
the chest the heart was rapidly removed and the left anterior
descending coronary artery was perfused using a Langendorff
apparatus. Ca2+-free JMM solution (Minimum Essential
Medium Eagle, Joklik modification; Sigma, product no. M-
0518), supplemented with taurine (2.5 g/l), pyruvic acid
(175 mg/l), ribose (750 mg/l), allopurinol (13.5 mg/l) and
NaH2PO4 (200 mg/l), was used during the initial 5 min of
perfusion to remove Ca2+ and blood from the tissue. After
addition of NaHCO3 (1.3 g/l), the pH of this perfusate was
7.0 when gassed with carbogen. Cell dispersion was performed
for 30 min in the same solution containing also collagenase
(660 mg/l, Worthington Cls-1), bovine albumin (2 g/l) and
CaCl2 (50 µM). During the isolation procedure the solutions
were gassed with carbogen and the temperature was maintained
at 37˚C. The cells were rod shaped and showed clear striation
when the external calcium was restored. Before use, the cells
were stored overnight at 14˚C in modified JMM solution
(pH 7.4).
MAGYAR et al:  EFFECTS OF FLUOXETINE ENANTIOMERS IN NEURAL AND CARDIAC TISSUES536
Action potentials were recorded from Ca2+-tolerant canine
ventricular cells superfused with modified Krebs solution
containing: 120 mM NaCl, 5.4 mM KCl, 2.7 mM CaCl2,
1.1 mM MgCl2, 1.1 mM NaH2PO4, 24 mM NaHCO3 and 6 mM
glucose. The solution was equilibrated with carbogen at a
temperature of 37˚C and the pH was adjusted to 7.4. Trans-
membrane potentials were recorded using glass microelectrodes
filled with 3 M KCl and having tip resistance between 20 and
40 MΩ. These electrodes were connected to the input of an
Axoclamp-2B amplifier (Axon Instruments). The cells were
continuously paced through the recording electrode at a steady
cycle length of 1000 ms using 1 ms wide rectangular current
pulses with 120% threshold amplitude. Action potentials were
digitized at 100 kHz using Digidata 1200 A/D card (Axon
Instruments) and stored for later analysis.
Ca2+ current was recorded from cells superfused with
oxygenated Tyrode solution containing 140 mM NaCl, 5.4 mM
KCl, 2.5 mM CaCl2, 1.2 mM MgCl2, 0.35 mM Na2HPO4, 5 mM
HEPES, 10 mM glucose and 3 mM 4-aminopyridine, at pH 7.4.
Suction pipettes, fabricated from borosilicate glass, had tip
resistance of 2 MΩ after filling with pipette solution composed
of 110 mM KCl, 40 mM KOH, 10 mM HEPES, 10 mM
EGTA, 20 mM TEACl, 3 mM K-ATP and 0.25 mM GTP. The
pH of this solution was adjusted to 7.2 with KOH. Membrane
currents were recorded with an Axopatch-1D amplifier (Axon
Instruments) using the whole cell configuration of the patch
clamp technique. After establishing high (1-10 GΩ) resistance
seal by gentle suction, the cell membrane beneath the tip of
the electrode was disrupted by further suction or by applying
1.5 V electrical pulses for 1-5 ms. The series resistance was
typically 4-8 MΩ before compensation (usually 50-80%).
Experiments were discarded when the series resistance was
high or substantially increasing during the measurement.
Outputs from the clamp amplifier were digitized at 20 kHz
using an A/D converter (Digidata 1200, Axon Instruments)
under software control (pClamp 6.0, Axon Instruments). Ca2+
current was measured at a rate of 0.2 Hz using depolarizing
voltage pulses of 400 ms duration clamped to 0 mV from the
holding potential of -40 mV. In cardiac cells fluoxetine was
added to the bath in a cumulative manner, applying each
concentration for 2 min. This period of time was sufficient to
achieve steady-state effects in both action potential and ion
current measurements.
Study of anticonvulsant effect of fluoxetine in mouse epilepsy
model. Mice of either sex, weighing 30±1.2 g, were injected
with pentylenetetrazole (100 mg/kg, s.c.) in order to evoke
epileptic activity. Single doses of 10 mg/kg fluoxetine (racemic,
S(+), or R(-) enantiomer) were administered subcutaneously
either 30 or 60 min before the application of pentylenete-
trazole. Seizure activity was evaluated continuously during the
period of 60 min following the injection of pentylenetetrazole
according to the following parameters. Survival rate (expressed
as percentage) was defined as the number of animals surviving
the 60-min post-pentylenetetrazole period divided by the total
number animals exposed to pentylenetetrazole in any particular
group. Seizure latency represents time elapsed from the
pentylenetetrazole-injection to the first appearance of seizures.
Survival duration was calculated only for those animals which
failed to survive the critical 60-min period of evaluation.
Statistics. All values presented are arithmetic means ± SEM.
Statistical significance was determined by using Student's t-test
performed following ANOVA. Differences were considered
significant when the P-value was <0.05.
The entire investigation conforms with the Guide for
the Care and Use of Laboratory Animals published by the
US National Institutes of Health (NIH publication no. 85-23,
revised 1996) and with the principles outlined in the
Declaration of Helsinki.
Results
Effect of fluoxetine on Ba2+ current in rat cochlear neurons. To
measure Ba2+ current flowing through Ca2+ channels, voltage
ramps rising from -100 mV to 40 mV during 200 ms were
applied. These ramps were repeated at a rate of 0.33 Hz, the
holding potential between the ramps was -75 mV. The
activation of Ca2+ channels during the ramps was seen as an
inward current mediated by Ba ions. The effect of fluoxetine
was measured as a reduction of the peak inward current.
Fluoxetine was applied in a non-cumulative manner. The cell
was exposed to one concentration of the drug (either S(+),
R(-), or the racemic form) for 20-30 sec using a fast flow
system. This time was sufficient to achieve steady-state
effect. Exposures were separated with 5-min periods of
washout. The next exposure (to another form of the same
concentration) was applied only after full reversion of the
drug-effect. All three forms of fluoxetine suppressed peak
Ba2+ current in a concentration-dependent manner studied
between concentrations of 0.1 and 100 µM, the concentration-
response curve obtained for racemic fluoxetine is shown in
Fig. 1A. Fitting these results to the Hill equation yielded a Kd
value of 22.3±3.5 µM and Hill coefficient of 0.87±0.1 (n=5).
Significant differences between the two enantiomers were
observed only at a concentration of 5 µM, where R(-)-
fluoxetine caused 28±3% decrease in the current in contrast
to the 18±2% reduction observed with 5 µM S(-)-fluoxetine
(P<0.05, n=13) (Fig. 1B). The effect of fluoxetine was fully
reversible even at the highest applied concentration of 100 µM
(Fig. 1C), where the current was largely suppressed by the
drug. One hundred µM of S(+), R(-) and racemic fluoxetine
caused comparable, 81±3%, 76±2% and 80±4% block,
respectively. Fluoxetine appeared to cause a certain degree of
desensitization, as its blocking effect decreased with time.
This desensitization was extremely rapid, it was over within a
few seconds after exposure to the drug (Fig. 1D). This de-
sensitization was prominent at low concentrations (0.1-1 µM),
but it was never observed with 100 µM fluoxetine.
Effect of fluoxetine enantiomers on action potential
configuration and L-type Ca2+ current in isolated canine
ventricular myocytes. Results obtained with racemic fluoxetine
were reported earlier (8), therefore, the effects of the S(+)
and R(-) enantiomers were studied and compared in these
experiments. Fluoxetine (0.1-10 µM) shortened action potential
duration (both APD50 and APD90) in a concentration-dependent
manner (Table I). This effect was associated with depression
of the plateau potential at 10 µM concentration. Concentrations
higher than 10 µM caused progressive depolarization and loss
of excitability, therefore, the effects of these concentrations
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Figure 1. Effect of fluoxetine on the calcium channels of pyramidal neurons isolated from the dorsal cochlear nucleus of the rat. (A), Concentration-dependent
effect of fluoxetine on peak Ba2+ current. Effects were evaluated after reaching steady-state level of inhibition (within 20-30 sec). Symbols and bars represent
mean ± SEM values, n=5. The blocking effect was statistically significant at each concentration comparing to control (not indicated). (B), Differential effects
of 5 µM S(+)-fluoxetine and R(-)-fluoxetine on the Ba2+ current. After taking the control trace, 5 µM S(+)-fluoxetine was applied first, and after reaching
steady-state effect (20 sec) the cell was superfused with 5 µM R(-)-fluoxetine for further 20 sec. (C), Reversibility of the effect of fluoxetine. The cell was
treated with 100 µM R(-)-fluoxetine for 25 sec, then washed with fluoxetine-free medium for 5 min. (D), Desensitization observed with 1 µM fluoxetine. After
taking control record, 1 µM S(+)-fluoxetine was applied. The first subsequent trace (dashed line) was taken immediately (3 sec) after application of fluoxetine,
dotted line indicates the trace taken after reaching the steady-state effect at 18 sec.
Table I. Effects of R(-)-fluoxetine and S(+)-fluoxetine on action potential characteristics in isolated canine ventricular myocytes.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
APD50 (ms) APD90 (ms) APA (mV) Vmax (V/s)
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
R(-)-fluoxetine (n=5)
Control 157±5 216±7 117.9±1.5 313±5
Fluoxetine 0.1 µM 150±4 209±4 118.1±1.4 314±6
Fluoxetine 1 µM 134±7a,b 202±4b 115.8±1.7 284±26
Fluoxetine 3 µM 98±9a,b 175±7a,b 115.1±1.6 276±29
Fluoxetine 10 µM 64±3a 154±10a 108.7±1.3a 229±24a
Washout 157±7 224±10 115.8±2.0 290±31
S(+)-fluoxetine (n=5)
Control 170±12 236±11 117.9±2.2 316±7
Fluoxetine 0.1 µM 156±12a 223±10a 118.1±2.2 314±11
Fluoxetine 1 µM 115±10a,b 192±10a,b 117.1±2.3 309±19
Fluoxetine 3 µM 82±8a,b 162±6a,b 117.0±2.1 295±25
Fluoxetine 10 µM 69±9a 154±5a 108.7±3.6a 231±26a
Washout 147±10a 233±9 117.9±2.4 305±16
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
APD50 and APD90 action potential duration measured at 50 and 90% repolarization, respectively. APA, action potential amplitude; Vmax,
maximum velocity of depolarization. Mean ± SEM values are given. aSignificant changes from control. bSignificant differences between
effects of R(-)-fluoxetine and S(+)-fluoxetine (P<0.05).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
were not analyzed. Significant differences in the APD-
shortening effect was observed between the S(+) and R(-)
enantiomer of fluoxetine: S(+)-fluoxetine shortened APD50
significantly from 0.1 µM, while R(-)-fluoxetine only from
1 µM. Furthermore, the magnitude of shortening was
significantly greater with 1 and 3 µM of S(+)-fluoxetine than
with the R(-) enantiomer. At 10 µM concentration, however,
no significant differences were observed between the effects
of the two enantiomers on action potential duration. At this
concentration both enantiomers also depressed action potential
upstroke: reduction of maximum velocity of depolarization
(Vmax) and action potential amplitude (APA) was observed. In
this respect no differences were seen between the enantiomers.
All these effects of fluoxetine developed rapidly (within 2 min)
and were fully reversible within the 5-min period of washout
(except the APD50 value following 10 µM of S(+)-fluoxetine).
In voltage clamped canine ventricular myocytes both
enantiomers of fluoxetine (n=5 for each) caused concentration-
dependent block of the peak Ca2+ current measured at 0 mV
(Fig. 2). Reduction in the amplitude of the peak current
was not accompanied with changes in the time course of
inactivation (Fig. 2A). Similarly to the effects on action
potentials, the suppressive effect of fluoxetine on ICa developed
rapidly and was largely reversible (Fig. 2B). The concentration-
response curve, presented in Fig. 2C, shows that both
enantiomers inhibited ICa significantly from the lowest (0.1 µM)
concentration studied, having moderate differences in the
Kd values (2.4±0.1 and 2.8±0.2 µM) and Hill coefficients
(1.41±0.05 and 1.24±0.13) obtained for the S(+) and R(-)
enantiomer, respectively. Significant differences in the blocking
effect was observed only at 3 and 10 µM concentrations:
S(+)-fluoxetine caused a higher degree of block than R(-)-
fluoxetine (56.3±2.2% versus 49.1±2.2% and 95.5±0.9%
versus 84.5±3.1% block with 3 and 10 µM S(+) and R(-)-
fluoxetine, respectively, P<0.05, n=5). The current was fully
abolished by 100 µM fluoxetine. In summary, cardiac
preparations appear to be more sensitive to the S(+) than
the R(-) enantiomer, as indicated by the stronger effect of
the former at 1-3 µM concentrations on action potential
duration and at 3-10 µM concentrations on ICa. In both cases
the effect of the R(-) enantiomer was more readily reversible
than that of the S(+) enantiomer (Table I and Fig. 2A and B).
Anticonvulsant effect of fluoxetine in pentylenetetrazole-treated
mice. From the 32 control animals (exposed to 100 mg/kg
pentylenetetrazole alone) 31 died within the subsequent 60 min
of evaluation (3.1% survival rate). Pretreatment with 10 mg/kg
fluoxetine 30 min before application of pentylenetetrazole
increased the rate of survival, however, this increase was highly
variable according to the fluoxetine enantiomer applied. Pre-
treatment with 10 mg/kg racemic or S(+)-fluoxetine produced
an increase of 8.9% for both groups, in contrast to the 33%
increase observed with the R(-) enantiomer. These differences
were much less pronounced when fluoxetine was applied
60 min prior to the injection of pentylenetetrazole (Fig. 3A).
The protective effect of 5 mg/kg fluoxetine (applied 60 min
before pentylenetetrazole) on the rate of survival was
negligible: only 1 animal survived in the R(-) and none in the
S(+)-fluoxetine group (out of 12 and 13, respectively, not
shown in Fig. 3).
Survival duration, monitored within the period of 60 min
following the injection of pentylenetetrazole, was increased
significantly by pretreatment with either 10 mg/kg racemic
or the same concentration of R(-)-fluoxetine, whereas the
protective effect was not significant in the case of the S(+)
enantiomer (Fig. 3B). Interestingly, this parameter appeared
to be insensitive to the time of fluoxetine-treatment, since the
values were almost identical in the cases of 30 and 60 min
pretreatment. Survival duration was also longer with 5 mg/kg
R(-) than S(+)-fluoxetine (15.3±4 versus 8.8±1.8 min survivals
were observed, n=12 and n=13, respectively, not shown).
Qualitatively similar increase in seizure latency was obtained
with: 10 mg/kg racemic or R(-)-fluoxetine, but not the S(+)
enantiomer (Fig. 3C).
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Figure 2. Effect of the R(-) and S(+) enantiomer of fluoxetine on the Ca2+
current in canine ventricular cardiomyocytes. (A), Superimposed ICa records
obtained before, during (2 min), and after superfusion with 3 µM fluoxetine.
Washout lasted for 5 min. Currents were measured during step depolarizations
to 0 mV, each lasting for 400 ms, applied from the holding potential of -40 mV
at a rate of 0.2 Hz. (B), Representative record showing the time scale of
development and reversion of the fluoxetine-induced changes in ICa. The drug
was applied in a cumulative manner (a, control; b, 0.1; c, 1; d, 3; e, 10; f,
30 µM fluoxetine, each concentration for 2 min, g: 5 min washout). (C),
Cumulative concentration-response curve obtained with the S(+) and R(-)
enantiomers of fluoxetine in canine ventricular myocytes (n=5 for each).
The solid line was generated by fitting data to the Hill equation. Symbols and
bars represent mean values ± SEM, asterisks indicate significant differences
(P<0.05) between the effects of the two enantiomers.
Discussion
Anticonvulsant action of fluoxetine. Our present results
indicate that fluoxetine exerts an anticonvulsant action in the
pentylentetrazole-induced seizure model. These data are in
accordance with those of previous studies demonstrating
an anticonvulsant effect of fluoxetine in other models of
epilepsy. Fluoxetine was found to be effective against maximal
electroshock-induced tonic extension in rats (44), audiogen
seizures in mice and rats (21,25), and focally evoked limbic
motor seizures in rats (22). Several clinical observations and
animal studies showed that fluoxetine enhanced the anti-
convulsant potency of various antiepileptic drugs (19,20,45-47).
Regarding the effective anticonvulsant dose of the drug,
fluoxetine exerted 50% protective effect at 5 mg/kg in the
limbic motor seizure model, whereas, in the genetically
epilepsy-prone rats (GEPR-9) the ED50 was ~16 mg/kg. In
our present seizure model fluoxetine showed a significant
anticonvulsant action at the dose of 10 mg/kg. We found a
marked difference in the anticonvulsant activity of the two
enantiomers, since R(-)-fluoxetine was more potent to increase
the survival rate than the S(+) enantiomer. The time-course
of anticonvulsant action of racemic and R(-)-fluoxetine
was also different. Racemic fluoxetine exhibited equal anti-
convulsant activity applied either 30 or 60 min before the
pentylentetrazole-injection, while R(-)-fluoxetine had stronger
anticonvulsant action when applied 30 min before the
convulsant drug. The opposite was observed with the S(+)
enantiomer. These observations can be well explained by
recent results indicating considerable differences in the
pharmacokinetic properties of the two enantiomers of
fluoxetine (39-41). S(+)-fluoxetine was found to be more
slowly eliminated than the R(-) enantiomer, and it was
suggested that its N-demethyl metabolite, S(+)-norfluoxetine
is more potent than R(-)-norfluoxetine. Both metabolites may
accumulate on chronic treatment with racemic fluoxetine (40).
In spite of previous data reporting that serotonin is
involved in regulation of seizure susceptibility (44,48-50), it
seems unlikely that inhibition of serotonin reuptake is the
only mechanism by which fluoxetine exerts its anticonvulsant
effect. Fluoxetine was shown to suppress the high K+-induced
burst firing in rat hippocampal neurons (10) considered as a
model for epilepsy not involving serotonergic transmission
(51). Thus the other possible explanation for the anticonvulsant
action of fluoxetine may be related to its inhibitory effect on
ionic channels. Several reports indicated that altered activity
of voltage-gated Na+ and Ca2+ channels was involved in the
enhancement of neuronal discharges during epilepsy (51-53),
and conventional anticonvulsant drugs were found to block
voltage-dependent Na+ and Ca2+ channels (11,13,14,53).
Our previous results demonstrating that fluoxetine was a
considerably more potent inhibitor of Ca2+ than Na+ channels
support the possibility that inhibition of Ca2+ channels by
fluoxetine may contribute to its anticonvulsant action (10).
Effects on calcium channels. In the present study we have
compared the actions of racemic, R(-) and S(+)-fluoxetine
on calcium channels in isolated rat cochlear neurons and
canine ventricular myocytes. We have shown that fluoxetine
decreased the high-voltage activated neuronal Ca2+ current
(mainly L-type) in a concentration-dependent manner, and at
a concentration of 5 µM this effect of R(-)-fluoxetine was
significantly greater than that of the S(+) enantiomer. In our
experiments, performed in cohlear neurons, the IC50 for
suppression of ICa was 22.3 µM suggesting that the sensitivity
of these neurons to fluoxetine is lower than that was seen in
hippocampal cells (10). On the other hand, blocking potency
on ICa, comparable to our results, were obtained in PC12 cells
(IC50 = 13 µM) (54) and in synaptosomes (for inhibition of
calcium uptake, IC50 = 27 µM) (55). The discrepancy between
the IC50 values may likely be attributed to differences in the
dominant Ca2+ channel type in the neurons examined.
The lower range of fluoxetine concentrations (0.1-5 µM)
blocking neuronal Ca2+ current in this study overlaps the
therapeutic plasma concentrations (0.15-1.5 µM) of the drug.
Under certain conditions (e.g. in case of drug interactions or
reduced metabolism in elderly) the plasma concentration of
fluoxetine can reach even higher levels. Moreover, during
chronic treatment fluoxetine was shown to accumulate in
human brain twenty times higher than its plasma level (56,57).
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Figure 3. Anticonvulsant effect of the fluoxetine enantiomers in pentylene-
tetrazole treated mice. Single doses of fluoxetine (S(+), R(-) or racemic, 10 mg/
kg) were administered either 30 or 60 min before the application of pentylene-
tetrazole (100 mg/kg). (A), Rate of survival, expressed as percentage, was
defined as the number of animals surviving the 60-min post-pentylenetetrazole
period divided by the total number animals exposed to pentylenetetrazole in
any particular group (indicated in parentheses). (B), Average survival duration.
Only those animals which failed to survive the critical 60-min period of
evaluation were included. (C), Seizure latency represents time elapsed from
the pentylenetetrazole-injection to the first appearance of seizures. Columns
and bars represent mean ± SEM values, asterisks indicate significant
differences (P<0.05) comparing to the pentylenetetrazole-treated (control)
group.
Thus, a significant inhibition of Ca2+ channels by fluoxetine
may occur in a patient chronically treated with fluoxetine,
exerting its anticonvulsant or antimigraine activity.
In isolated canine cardiomyocytes both enantiomers
shortened action potential duration, but the effectivity of the
two enantiomers was different. S(+)-fluoxetine shortened
APD50 significantly from the concentration of 0.1 µM, while
R(-)-fluoxetine from 1 µM only. In addition, the magnitude
of shortening was also significantly greater in the case of 1
and 3 µM of S(+)-fluoxetine. At the higher concentration
of 10 µM both enantiomers decreased also action potential
amplitude and the maximum rate of depolarization. No
difference was observed between the two enantiomers from
this point of view indicating an equal potency of blocking
cardiac Na+ channels. The shortening effect of fluoxetine on
cardiac action potentials may be best explained with inhibition
of the L-type Ca2+ channel. Indeed, both enantiomers blocked
peak Ca2+ current significantly, however, this effect was more
pronounced at 3 and 10 µM concentrations of the S(+) than
the R(-) enantiomer. The 2.4 and 2.8 µM Kd values, obtained
for S(+) and R(-)-fluoxetine in this study, is very close to the
value of 3 µM, reported previously by Pacher et al (8) with
racemic fluoxetine in canine ventricular cells. These cardiac
electrophysiological actions of fluoxetine enantiomers may
be proarrhythmic due to impairment of atrioventricular or
intraventricular conduction and shortening of repolarization.
Moreover, the negative inotropic action observed in rat
papillary muscle (8) and the vasodilator effect of racemic
fluoxetine (58) may also be due to inhibition of L-type Ca2+
channels and may explain the cardiovascular side-effects
(dysrhythmias, syncope) observed occasionally in patients
treated with fluoxetine (26,27,29,30,32-34,36,38).
In conclusion, our present data indicate that the two
enantiomers of fluoxetine have different anticonvulsant effects
and inhibitory activities on neuronal and cardiac Ca2+ channels
at micromolar concentrations. While R(-)-fluoxetine exerts
stronger anticonvulsant action associated with inhibition of
neuronal Ca2+ channels, the S(+) form appears to be more
potent in shortening of cardiac action potential due to inhibition
of cardiac Ca2+ channels. It is important to emphasize that
these differences in the action of the two enantiomers on
Ca2+ current were evident only within a narrow range of
concentrations (3-10 µM) and were not great in magnitude.
It is tempting to speculate, however, that the S(+) isomer
may be more responsible for the undesired cardiovascular
side-effects that sometimes develop during chronic fluoxetine
treatment. Used as an antidepressant or anticonvulsant drug,
less severe cardiac side-effects are anticipated with R(-)-
fluoxetine.
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